Hansa Biopharma AB Statistics
Want to see SE:HNSA full AI Analyst Report?
Hansa Biopharma AB (HNSA) Stock Statistics & Valuation Metrics
Total Valuation
Hansa Biopharma AB has a market cap or net worth of SEK 4.77B. The enterprise value is SEK 2.95B.
- Market Cap
- SEK 4.77B
- Enterprise Value
- SEK 2.95B
Share Statistics
Hansa Biopharma AB has 101,763,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 101,763,220
- Owned by Insiders
- ―
- Owned by Institutions
- 3.36%
Financial Efficiency
Hansa Biopharma AB’s return on equity (ROE) is 6.00 and return on invested capital (ROIC) is -57.78%.
- Return on Equity (ROE)
- 6.00
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -57.78%
- Return on Capital Employed (ROCE)
- -0.69
- Revenue Per Employee
- 1.78M
- Profits Per Employee
- -4.27M
- Employee Count
- 125
- Asset Turnover
- 0.19
- Inventory Turnover
- 13.63
Valuation Ratios
The current PE Ratio of Hansa Biopharma AB is -5.93. Hansa Biopharma AB’s PEG ratio is 10.12.
- PE Ratio
- -5.93
- PS Ratio
- 15.49
- PB Ratio
- -6.82
- Price to FCF
- 9.17
- Price to Operating Cash Flow
- 8.85
- PEG Ratio
- 10.12
Income Statement
In the last 12 months, Hansa Biopharma AB had revenue of 222.26M and earned -534.11M in profits. Earnings per share was -6.52.
- Revenue
- 222.26M
- Gross Profit
- 138.71M
- Operating Income
- -520.71M
- Pretax Income
- -531.84M
- Net Income
- -534.11M
- EBITDA
- -483.82M
- Earnings Per Share (EPS)
- -6.52
Cash Flow
In the last 12 months, operating cash flow was 528.26M and capital expenditures -18.67M, giving a free cash flow of 509.59M billion.
- Operating Cash Flow
- 528.26M
- Free Cash Flow
- 509.59M
- Free Cash Flow per Share
- 5.11
Dividends & Yields
Hansa Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.91%
- Earnings Yield
- -17.13%
Stock Price Statistics
- Beta
- 0.61
- 52-Week Price Change
- 73.74%
- 50-Day Moving Average
- 37.68
- 200-Day Moving Average
- 34.47
- Relative Strength Index (RSI)
- 72.07
- Average Volume (3m)
- 630.19K
Important Dates
Hansa Biopharma AB upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Hansa Biopharma AB as a current ratio of 1.94, with Debt / Equity ratio of -1049.33%
- Current Ratio
- 1.94
- Quick Ratio
- 1.92
- Debt to Market Cap
- 0.33
- Net Debt to EBITDA
- -0.48
- Interest Coverage Ratio
- -4.43
Taxes
In the past 12 months, Hansa Biopharma AB has paid 2.27M in taxes.
- Income Tax
- 2.27M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Hansa Biopharma AB EV to EBITDA ratio is -7.57, with an EV/FCF ratio of 8.40.
- EV to Sales
- 14.20
- EV to EBITDA
- -7.57
- EV to Free Cash Flow
- 8.40
- EV to Operating Cash Flow
- 8.11
Balance Sheet
Hansa Biopharma AB has SEK 1.34B in cash and marketable securities with SEK 948.28M in debt, giving a net cash position of SEK 388.90M billion.
- Cash & Marketable Securities
- SEK 1.34B
- Total Debt
- SEK 948.28M
- Net Cash
- SEK 388.90M
- Net Cash Per Share
- SEK 3.82
- Tangible Book Value Per Share
- -SEK 9.29
Margins
Gross margin is 54.60%, with operating margin of -194.67%, and net profit margin of -265.34%.
- Gross Margin
- 54.60%
- Operating Margin
- -194.67%
- Pretax Margin
- -264.63%
- Net Profit Margin
- -265.34%
- EBITDA Margin
- -187.57%
- EBIT Margin
- -195.48%
Analyst Forecast
The average price target for Hansa Biopharma AB is SEK 103.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- SEK 103.00
- Price Target Upside
- 119.90% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 68.88%
- EPS Growth Forecast
- 10.63%
Scores
- Smart Score
- ―
- AI Score
- 56
